4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
20/20 Biolabs, Inc. (AIDX) operates in the Medical Devices industry and is headquartered in Gaithersburg, United States with about 4 employees. Its market capitalization is roughly $6 million. In the fiscal year ended 2025-12-31, AIDX reported $2M in revenue and ($4M) in net income.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.
Interactive charts & full statements → Open the AIDX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | $2M | $2M | $1M |
| Gross Profit | $1M | $0M | $0M |
| Operating Income (EBIT) | ($3M) | ($6M) | ($6M) |
| Net Income | ($4M) | ($6M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($1M) | ($1M) | ($1M) | ($1M) |
| Net Income | ($2M) | ($1M) | ($1M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | $4M | $4M | $6M |
| Total Liabilities | $4M | $2M | $2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AIDX viewer.
About TickerBase · Data methodology & sources